SurModics surges on Merck ophthalmic deal
This article was originally published in Clinica
Executive Summary
Drug-delivery products firm SurModics saw its share price soar around 19% this week, after announcing it had partnered with pharmaceutical giant Merck & Co in an ophthalmic licensing and research deal.